2021.06
Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
![1651731782874082.jpg 1.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731782874082.jpg)
![1651731788624628.jpg 2.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731788624628.jpg)
![1651731793107515.jpg 3.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731793107515.jpg)
![1651731798334422.jpg 4.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731798334422.jpg)
![1651731803675834.jpg 5.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731803675834.jpg)
![1651731808248254.jpg 6.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731808248254.jpg)
![1651731817988163.jpg 7.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731817988163.jpg)
![1651731824551648.jpg 8.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731824551648.jpg)
![1651731831327408.jpg 9.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731831327408.jpg)
![1651731851680253.jpg 10.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731851680253.jpg)
![1651731859981221.jpg 11.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731859981221.jpg)
![1651731888750546.jpg nment with high mutational burden in lung cancer_12.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731888750546.jpg)
![1651731896139969.jpg nment with high mutational burden in lung cancer_13.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731896139969.jpg)
![1651731903932365.jpg nment with high mutational burden in lung cancer_14.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731903932365.jpg)
![1651731909515065.jpg nment with high mutational burden in lung cancer_15.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731909515065.jpg)
![1651731918539225.jpg nment with high mutational burden in lung cancer_16.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731918539225.jpg)
![1651731931461305.jpg nment with high mutational burden in lung cancer_17.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731931461305.jpg)
![1651731937463208.jpg nment with high mutational burden in lung cancer_18.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731937463208.jpg)
![1651731942757636.jpg nment with high mutational burden in lung cancer_19.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731942757636.jpg)
![1651731948244345.jpg nment with high mutational burden in lung cancer_20.jpg](http://english.genecast.com.cn/uploads/img/ueditor/image/20220505/1651731948244345.jpg)
Pictures are from Journal for ImmunoTherapy of Cancer.
Nivolumab-associated DRESS in a genetic susceptible individual
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers